The research team of Dr’s Fiona Smaill and Zhou Xing, IIDR members and professors within McMaster University’s Department of Pathology and Molecular Medicine, is looking for healthy participants who were born outside of Canada to enroll in their Canadian Institutes of Health Research – supported tuberculosis booster vaccine study.
The purpose of this Phase 1, open-label clinical trial is to evaluate the safety and immunogenicity of their adenovirus-based tuberculosis vaccine, administered by aerosol.
If interested in participating in the study, please contact email@example.com, or learn more by visiting www.mcmaster-tbstudy.com and the links below. Remuneration will be provided for all participants.
- McMaster University Receives $3.6M in Federal Funds to Support Development of New TB Vaccine
- A Vaccine for Tuberculosis – The Final Frontier
- The Role of Dendritic Cell Populations In T-Cell Activation Following Human Pulmonary Tuberculosis Infection
- McMaster Lab Develops New Tuberculosis Vaccine
- March 24 is World TB Day